Read this topic

Antidepressant mechanism matters because it is the single fastest way to predict a drug's benefit AND its side-effect profile before a patient ever swallows a tablet. Psychiatry offers a dozen-plus antidepressants, and a fresh MBBS graduate could easily try to memorise every one as an isolated fact. That approach collapses under exam pressure and under real prescribing pressure alike. The far more durable approach is to sort each drug by WHICH chemical messenger, or NEUROTRANSMITTER (a chemical signal that nerve cells use to communicate), it raises and HOW it raises it, because that single fact predicts almost everything else about the drug: its likely benefit, its common side effects, and which other drugs it dangerously interacts with.

An antidepressant is a drug used mainly to treat depression by increasing the activity of monoamine neurotransmitters, chiefly serotonin and noradrenaline, at the synapse (the tiny gap between two nerve cells where chemical signalling happens). Most classes achieve this the same basic way: they block a REUPTAKE PUMP, a protein that normally recycles the neurotransmitter back into the nerve cell that released it, so blocking it leaves more neurotransmitter sitting in the synapse to keep signalling.

The trap fresh graduates fall into is assuming that because two drugs both 'treat depression', they behave the same way in the body. They do not. A drug's EXTRA actions, the receptors it blocks beyond its main reuptake-pump target, explain almost all of its unwanted effects, and those extra actions vary enormously between classes. A tricyclic and an SSRI (selective serotonin reuptake inhibitor) can both lift mood equally well in a trial, yet one causes a dry mouth, blurred vision and danger in overdose, while the other mostly does not, purely because of what else each molecule happens to bind.

SSRIs selectively block the serotonin transporter (SERT), the pump that recycles serotonin, with relatively little action elsewhere, which is why they are usually the first-line choice: effective, with a comparatively narrow side-effect and interaction footprint. SNRIs (serotonin-noradrenaline reuptake inhibitors) such as venlafaxine and duloxetine block both the serotonin and the noradrenaline pumps; venlafaxine is mainly serotonergic (serotonin-raising) at low dose but gains noradrenergic (noradrenaline-raising) action as the dose rises, a dose-dependent mechanism that is a classic exam point. Tricyclic antidepressants (TCAs) block both pumps too, but they also block muscarinic receptors (causing dry mouth, constipation and blurred vision), histamine H1 receptors (causing sedation and weight gain) and alpha-1 receptors (causing dizziness on standing), and are dangerous in overdose because of cardiac toxicity. Mirtazapine works differently again: it blocks presynaptic alpha-2 'brake' receptors, so instead of blocking a pump it releases more noradrenaline and serotonin directly, and its strong H1 blockade makes it sedating, useful deliberately in a patient with poor sleep and appetite. MAOIs (monoamine oxidase inhibitors) block the enzyme that breaks monoamines down entirely, raising serotonin, noradrenaline and dopamine together, but require a tyramine-restricted diet to avoid a dangerous hypertensive crisis. Bupropion blocks the noradrenaline and dopamine pumps, sparing sexual function (a common complaint with serotonergic drugs) but lowering the seizure threshold. Vortioxetine and agomelatine sit further out: vortioxetine acts on the serotonin pump plus several serotonin receptors, while agomelatine is a melatonin-receptor agonist (a drug that activates the melatonin receptor) and 5-HT2C blocker, and needs liver-function monitoring.

For example, a patient who needs an antidepressant but cannot tolerate any sedation makes the mechanism logic concrete. Because mirtazapine and the tricyclics both carry strong histamine H1 blockade, both would likely cause drowsiness in this patient, so a prescriber reasoning from mechanism, not habit, would steer instead toward an SSRI or an SNRI, which have little or no H1 action. In a second scenario, a patient troubled by loss of libido on an SSRI illustrates the same logic in reverse: switching to bupropion, which does not touch the serotonin pump at all, sidesteps that particular side effect, at the cost of a lower seizure threshold that must be weighed if the patient has any seizure risk. In both cases the prescribing decision falls straight out of knowing which pumps and receptors each drug hits.

It is easy to conflate 'serotonergic' with 'SSRI', but SNRIs, tricyclics, MAOIs and vortioxetine are all serotonergic too, and stacking any two of these classes together risks serotonin syndrome, a separate high-yield topic in its own right. It is equally easy to conflate sedation with efficacy; a sedating drug like mirtazapine is not more effective at treating the underlying depression than a non-sedating SSRI, it is simply doing something extra (blocking histamine) that a clean reuptake inhibitor is not.

There is no 'diagnosis' of a mechanism itself, but choosing the right antidepressant starts from correctly diagnosing depression against ICD-11 or DSM-5 criteria, then screening for contraindications, cardiac disease before a tricyclic, seizure risk before bupropion, and a careful medication and dietary history before an MAOI, since these determine which mechanism class is even safe to start.

NICE guidance on depression in adults recommends an SSRI as first-line for most patients, given its comparatively favourable side-effect and safety profile in overdose. BNF and Maudsley Prescribing Guidelines both stress checking for interacting drugs (other serotonergic agents, MAOIs, St John's wort) before starting any new agent, and both advise a full washout period when switching to or from an MAOI. If an SSRI fails or is not tolerated, mechanism-based switching, to an SNRI, mirtazapine, or another class depending on which side effect was the problem, is standard second-line practice rather than blind trial and error.

When a stem describes a specific side-effect profile (dry mouth plus blurred vision, or sedation plus weight gain, or sexual side effects), work backwards from the receptor causing that effect (muscarinic, histaminic, serotonergic) to identify the drug class, rather than trying to recall each drug name from memory alone.

Antidepressant classes are named for which reuptake pump or receptor they act on, and that single mechanistic fact predicts both their benefit and their entire side-effect and interaction profile.